Pharmaceutical compositions containing procyanidins from rhizophora mangle bark fractions

NOVELTY – Procyanidin compound (I), is new. USE – Procyanidin compound used in medicament and pharmaceutical composition for treating non-specific ulcerative rectocolitis and Crohn’s disease (all claimed). ADVANTAGE – The procyanidin compound provides new molecular fractions potentially for treating inflammatory gastrointestinal diseases, as well as possible systemic immunological interactions involved in the administration of these fractions. The pharmaceutical composition improves lesion of colon mucosa, antioxidant glutathione contents and enzyme (glutathione peroxidase or catalase) contents and modulation of inflammation markers (myeloperoxidase, thiobarbituric acid reactive substances, cyclooxygenase-1 or cyclooxygenase-2) and cytokines (tumor necrosis factor-alpha, interleukin-6 or interleukin-12). DETAILED DESCRIPTION – Procyanidin compound of formula (I), is new. An INDEPENDENT CLAIM is included for a pharmaceutical composition, which comprises 0.5 mg/kg of butanol fraction obtained by using ethyl acetate. DESCRIPTION OF DRAWING(S) – The drawing shows a schematic first-order mass spectrum of butanol fraction in full-scan mode.

Main Application Field

B02 (Fused ring heterocyclics.)

INVENTORS:

BRITO ALBA REGINA MONTEIRO SOUZA
DE FARIA FELIPE MEIRA

699_PROCIANIDINAS

Patent number: WO2014131095-A1;BR102013005019-A2

PATENT STATUS:

For information contact Inova Unicamp

FOR ADDITIONAL INFORMATION:

parcerias@inova.unicamp.br

+55 (19) 3521-5207 / 2607